Literature DB >> 31933908

Differential expression of HSP90 isoforms and their correlations with clinicopathologic factors in patients with colorectal cancer.

Kisu Kim1, Hyoun Wook Lee1, Eun Hee Lee1, Moon-Il Park1, Jae Seok Lee1, Mee-Seon Kim1, Kyungeun Kim2, Mee Sook Roh3, Min Gyoung Pak3, Ji Eun Oh4, Kwang Min Kim4, Jung Won Lee4, Tae Gyu Kim5, Hyun-Yeol Nam6.   

Abstract

Heat shock protein 90 (HSP90), a molecular chaperone, plays critical roles in cellular protection against various stressful stimuli and in the regulation of cellular growth and apoptosis. HSP90 has four human isoforms; HSP90α, HSP90β, glucose related protein 94 (GRP94), and tumor necrosis factor (TNF) receptor-associated protein 1 (TRAP1). We evaluated the differential expression of these HSP90 isoforms in colorectal cancer (CRC) and correlated their expression levels with clinicopathological factors and patient survival rates. We performed immunohistochemical staining for HSP90α, HSP90β, GRP94, and TRAP1 in 129 CRC tumor samples and found that HSP90α expression was significantly associated with advanced pT stage (P = 0.011) and shorter recurrence-free survival (RFS) (P = 0.010), whereas GRP94 expression was correlated with low grade (P = 0.029) and better RFS (P < 0.001). HSP90β and TRAP1 had no prognostic impact, although HSP90β expression was positively correlated with tumor size (P = 0.008). Based on our results, HSP90α and GRP94 are potential prognostic biomarkers of CRC. In addition, the differences in expression and functional activities among four HSP90 isoforms imply that isoform selectivity should be seriously considered when HSP90 inhibitors are studied or adopted for the treatment of CRC. IJCEP
Copyright © 2019.

Entities:  

Keywords:  Colorectal cancer; GRP94; HSP90; TRAP1; immunohistochemistry; prognosis

Year:  2019        PMID: 31933908      PMCID: PMC6945153     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  31 in total

Review 1.  Heat shock proteins.

Authors:  M J Schlesinger
Journal:  J Biol Chem       Date:  1990-07-25       Impact factor: 5.157

2.  High-level expression of Hsp90β is associated with poor survival in resectable non-small-cell lung cancer patients.

Authors:  Seok-Hyun Kim; Jun Ho Ji; Kyung Tae Park; Ji Hyun Lee; Kyung Woo Kang; Jae Hong Park; Sang Won Hwang; Eun Hee Lee; Yu Ji Cho; Yi Yeong Jeong; Ho-Cheol Kim; Jong Deog Lee; Inseok Jang; Jong Sil Lee; Hyoun Wook Lee; Gyeong-Won Lee
Journal:  Histopathology       Date:  2015-03-26       Impact factor: 5.087

3.  Overexpression of GRP78 and GRP94 is involved in colorectal carcinogenesis.

Authors:  Hiroyuki Takahashi; Jian-ping Wang; Hua-chuan Zheng; Shinji Masuda; Yasuo Takano
Journal:  Histol Histopathol       Date:  2011-06       Impact factor: 2.303

4.  Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma.

Authors:  Xiao-Ping Wang; Fan-Rong Qiu; Guo-Zhen Liu; Rui-Fen Chen
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

5.  Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression.

Authors:  Z Milicevic; D Bogojevic; M Mihailovic; M Petrovic; Z Krivokapic
Journal:  Int J Oncol       Date:  2008-06       Impact factor: 5.650

6.  Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas.

Authors:  Hua-chuan Zheng; Hiroyuki Takahashi; Xiao-han Li; Takuo Hara; Shinji Masuda; Yi-fu Guan; Yasuo Takano
Journal:  Hum Pathol       Date:  2008-05-14       Impact factor: 3.466

Review 7.  Inhibition of HSP90 molecular chaperones: moving into the clinic.

Authors:  Rocio Garcia-Carbonero; Amancio Carnero; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2013-08       Impact factor: 41.316

Review 8.  Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives.

Authors:  Nadia Boroumand; Hossein Saghi; Amir Avan; Amirhossein Bahreyni; Mikhail Ryzhikov; Majid Khazaei; Seyed Mahdi Hassanian
Journal:  J Pharm Pharmacol       Date:  2017-10-04       Impact factor: 3.765

9.  Comparative analysis of Hsp10 and Hsp90 expression in healthy mucosa and adenocarcinoma of the large bowel.

Authors:  Francesca Rappa; Carmelo Sciume; Margherita Lo Bello; Celeste Caruso Bavisotto; Antonella Marino Gammazza; Rosario Barone; Claudia Campanella; Sabrina David; Francesco Carini; Federica Zarcone; Stefano Rizzuto; Adriana Lena; Giovanni Tomasello; Maria Laura Uzzo; Giovanni Francesco Spatola; Giuseppe Bonaventura; Angelo Leone; Aldo Gerbino; Francesco Cappello; Fabio Bucchieri; Giovanni Zummo; Felicia Farina
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

10.  Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues.

Authors:  Min Gyoung Pak; Hyong Jong Koh; Mee Sook Roh
Journal:  Diagn Pathol       Date:  2017-01-14       Impact factor: 2.644

View more
  7 in total

1.  A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.

Authors:  Lucía Zhu; Diana Retana; Pedro García-Gómez; Laura Álvaro-Espinosa; Neibla Priego; Mariam Masmudi-Martín; Natalia Yebra; Lauritz Miarka; Elena Hernández-Encinas; Carmen Blanco-Aparicio; Sonia Martínez; Cecilia Sobrino; Nuria Ajenjo; Maria-Jesus Artiga; Eva Ortega-Paino; Raúl Torres-Ruiz; Sandra Rodríguez-Perales; Riccardo Soffietti; Luca Bertero; Paola Cassoni; Tobias Weiss; Javier Muñoz; Juan Manuel Sepúlveda; Pedro González-León; Luis Jiménez-Roldán; Luis Miguel Moreno; Olga Esteban; Ángel Pérez-Núñez; Aurelio Hernández-Laín; Oscar Toldos; Yolanda Ruano; Lucía Alcázar; Guillermo Blasco; José Fernández-Alén; Eduardo Caleiras; Miguel Lafarga; Diego Megías; Osvaldo Graña-Castro; Carolina Nör; Michael D Taylor; Leonie S Young; Damir Varešlija; Nicola Cosgrove; Fergus J Couch; Lorena Cussó; Manuel Desco; Silvana Mouron; Miguel Quintela-Fandino; Michael Weller; Joaquín Pastor; Manuel Valiente
Journal:  EMBO Mol Med       Date:  2022-02-17       Impact factor: 12.137

Review 2.  Ins and Outs of Heat Shock Proteins in Colorectal Carcinoma: Its Role in Carcinogenesis and Therapeutic Perspectives.

Authors:  Batoul Abi Zamer; Waseem El-Huneidi; Mohamed Ahmed Eladl; Jibran Sualeh Muhammad
Journal:  Cells       Date:  2021-10-24       Impact factor: 6.600

Review 3.  Pimitespib: First Approval.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2022-09       Impact factor: 11.431

4.  BidSi6 and BidEL isoforms as a potential marker for predicting colorectal adenomatous polyps.

Authors:  Flora Forouzesh; Fatemeh Sadat Kia; Ehsan Nazemalhosseini-Mojarad
Journal:  BMC Med Genomics       Date:  2022-06-06       Impact factor: 3.622

Review 5.  The Role of Mitochondria Dysfunction in Inflammatory Bowel Diseases and Colorectal Cancer.

Authors:  Patrycja Kłos; Siarhei A Dabravolski
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 6.  Targeting extracellular Hsp90: A unique frontier against cancer.

Authors:  Rebecca A Sager; Farzana Khan; Lorenzo Toneatto; SarahBeth D Votra; Sarah J Backe; Mark R Woodford; Mehdi Mollapour; Dimitra Bourboulia
Journal:  Front Mol Biosci       Date:  2022-08-17

Review 7.  Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy.

Authors:  Ji Woong Kim; Yea Bin Cho; Sukmook Lee
Journal:  Cells       Date:  2021-03-17       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.